Malmö, July 5, 2017
Acarix Receives First German Commercial Order For CADScor®System For Early Detection Of Coronary Artery Disease From Private Cardiology Clinic In Berlin
Commercialization program on track as interest grows following ACC data presentation
Acarix AB (publ) ("Acarix" or the "Company") today announced that a private cardiology clinic in Berlin headed by Dr. med. Niels Jacobsohn has placed the first order in the important German market for its CADScor®System for non-invasive, non-radiation acoustic detection of Coronary Artery Disease (CAD). A recently presented study at the American College of Cardiology (ACC) 2017 Annual Scientific Meeting showed that CADScor®System rules out CAD with 97% negative predictive value. The German order follows a placement in a key Danish hospital setting.
The CADScor®System combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patient specific CAD-score in less than 10 minutes.
Prof. Dr. Christian Hamm, Medical Director at Kerckhoff Klinik, Bad Nauheim, Director at Med. Klinik I, University Hospital, Giessen and past President of the German Society of Cardiology commented on the release of the CADScor®System in the German market: "We have a multitude of diagnostic methods to examine patients with suspected stable angina in the hospital setting, but accurate, easy to use, and non-invasive diagnostic aids for an optimal pre-hospital triage are missing. CADScor®System has the potential to improve the diagnostic pathway for the benefit of both patients and cost-effectiveness."
The decision to purchase CADScor®System was explained by Dr. med. Niels Jacobsohn, head of the private Cardiology Clinic in Alt-Tegel, Berlin: "In Germany, nearly one million invasive cardiac catheter examinations are performed every year. A large proportion of these investigations leads to no finding. Patients, for whom Coronary Artery Disease can be ruled out without an invasive cardiac catheter examination, should not be exposed to the stress and risk associated with invasive diagnostics. New innovative technologies, such as the Acarix CADScor®System, help to avoid invasive procedures in patients without Coronary Artery Disease and additionally to reduce costs."
Acarix CEO Søren Rysholt Christiansen commented: "We are very pleased that having thoroughly evaluated the CADScor®System, Dr. med. Niels Jacobsohn, head of the private Cardiology Clinic in Alt-Tegel, Berlin will become our first German customer. To launch the CADScor®System first in the private sector is in keeping with the company's strategy in anticipation of future reimbursement and launch in the larger public-sector market.
Contacts:
Acarix A/S
Søren Rysholt Christiansen, CEO, E-mail: [email protected] Phone: +45 2777 1112
This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on July 5, 2017.
Notes to editors:
Acarix , CADScor®System and cardiac sound measurement
Acarix A/S was established in 2009, and since 2010 investors SEED Capital (DK) and Sunstone Life Science Ventures (DK) have supported it towards market introduction. Acarix has attracted a highly-experienced management team who have held senior positions in international medical device companies – CEO Søren Rysholt Christiansen with ELOS Medtech, GN ReSound and Cook Medical.
Acarix's CADScor®System is based on engineering excellence in sound recording and signal processing. It has long been known that both cardiac contraction movement and turbulent flow can generate sound. Contraction related sounds are in lower frequency, whereas turbulent sounds in the streaming blood caused by partial obstruction (stenosis) in the coronary arteries are of higher frequencies. The detection of these murmurs is delicate, since the energy of the murmurs is very weak. Detecting and recording the coronary murmurs requires not only an advanced sensor but also means for proper attachment to the skin above the heart to optimize the recorded signal and to avoid external noise.
The Acarix CADScor®System has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed and displayed as a patient specific score, the CAD-score, on the device screen. The CADScor®System contains the necessary electronics to instruct professionals during use and to guide through the recording periods. The system also contains a docking station for daily qualification of the sensor. Further the system integrates with an adhesive patch for locking the sensor to a fixed position above the heart during the recording.
The software embedded in The Acarix CADScor®System ensures that adequate recording conditions are controlled at every examination.
The CADScor®System is CE Marked by TÜV in 2015.
Press photos: http://www.acarix.com/about-us/press-downloads/press-photos/.
See more at www.acarix.com
20170705 Press Release First German Customer_UK
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire
